<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1387</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>10605011</PubmedId>
            <Abstract>As a result of expression of the influenza hemagglutinin (HA) in the pancreatic islets, the repertoire of HA-specific CD8+ T lymphocytes in InsHA transgenic mice (D2 mice expressing the HA transgene under control of the rat insulin promoter) is comprised of cells that are less responsive to cognate Ag than are HA-specific CD8+ T lymphocytes from conventional mice. Previous studies of tolerance induction involving TCR transgenic T lymphocytes suggested that a variety of different mechanisms can reduce avidity for Ag, including altered cell surface expression of molecules involved in Ag recognition and a deficiency in signaling through the TCR complex. To determine which, if any, of these mechanisms pertain to CD8+ T lymphocytes within a conventional repertoire, HA-specific CD8+ T lymphocytes from B10.D2 mice and B10.D2 InsHA transgenic mice were compared with respect to expression of cell surface molecules, TCR gene utilization, binding of tetrameric KdHA complexes, lytic mechanisms, and diabetogenic potential. No evidence was found for reduced expression of TCR or CD8 by InsHA-derived CTL, nor was there evidence for a defect in triggering lytic activity. However, avidity differences between CD8+ clones correlated with their ability to bind KdHA tetramers. These results argue that most of the KdHA-specific T lymphocytes in InsHA mice are not intrinsically different from KdHA-specific T lymphocytes isolated from conventional animals. They simply express TCRs that are less avid in their binding to KdHA.</Abstract>
            <ArticleYear>2000</ArticleYear>
            <ArticlePages>191-200</ArticlePages>
            <ArticleTitle>Characterization of CD8+ T lymphocytes that persist after peripheral tolerance to a self antigen expressed in the pancreas.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Nugent</LastName>
                    <ForeName>C T</ForeName>
                </Author>
                <Author>
                    <LastName>Morgan</LastName>
                    <ForeName>D J</ForeName>
                </Author>
                <Author>
                    <LastName>Biggs</LastName>
                    <ForeName>J A</ForeName>
                </Author>
                <Author>
                    <LastName>Ko</LastName>
                    <ForeName>A</ForeName>
                </Author>
                <Author>
                    <LastName>Pilip</LastName>
                    <ForeName>I M</ForeName>
                </Author>
                <Author>
                    <LastName>Pamer</LastName>
                    <ForeName>E G</ForeName>
                </Author>
                <Author>
                    <LastName>Sherman</LastName>
                    <ForeName>L A</ForeName>
                </Author>
            </Authors>
            <Affiliations>Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT 06520, USA.</Affiliations>
            <ArticleChemicalList>Autoantigens;CD3 Complex;CD8 Antigens;Epitopes, T-Lymphocyte;H-2 Antigens;Hemagglutinin Glycoproteins, Influenza Virus;Receptors, Antigen, T-Cell</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Autoantigens(biosynthesis); CD3 Complex(physiology); CD8 Antigens(biosynthesis); Cell Differentiation(genetics; immunology); Cell Separation; Clone Cells; Cytotoxicity, Immunologic(genetics); Diabetes Mellitus, Experimental(genetics; immunology); Epitopes, T-Lymphocyte(immunology); H-2 Antigens(immunology; metabolism); Hemagglutinin Glycoproteins, Influenza Virus(immunology; metabolism); Immune Tolerance(genetics); Islets of Langerhans(immunology; metabolism); Mice; Mice, Transgenic; Protein Binding(immunology); Receptors, Antigen, T-Cell(biosynthesis; metabolism); Signal Transduction(genetics; immunology); Species Specificity; T-Lymphocyte Subsets(cytology; immunology; metabolism); T-Lymphocytes, Cytotoxic(cytology; immunology; metabolism)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>164</Volume>
                <Issue>1</Issue>
                <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
                <Issn>0022-1767</Issn>
                <MedlineTa>J Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>HA 518-526</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>IYSTVASSL</LinearSequence>
                        <StartingPosition>533</StartingPosition>
                        <EndingPosition>541</EndingPosition>
                        <SourceMolecule>
                            <IedbAccession>SRC133</IedbAccession>
                        </SourceMolecule>
                        <SourceOrganismId>211044</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>MyM</LocationOfData>
                <EpitopeId>29690</EpitopeId>
                <ReferenceStartingPosition>518</ReferenceStartingPosition>
                <ReferenceEndingPosition>526</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>SwissProt entry is for the hemagglutinin precursor, harboring a 17-aa signal sequence and the HA1 and HA2 chains. Without considering the signal region, the position of the epitope in the mature HA1+HA2 protein, according to that entry, would be 516-524.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 7</LocationOfData>
                        <TCellId>21789</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000211</OrganismId>
                                <Age>&gt; 8 wk.</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1200 HA units</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>T cell</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>IYSTVASSL</LinearSequence>
                                            <StartingPosition>533</StartingPosition>
                                            <EndingPosition>541</EndingPosition>
                                            <SourceMolecule>
                                                <IedbAccession>SRC133</IedbAccession>
                                            </SourceMolecule>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>3 wks after infection, mice were boosted with 10&lt;sup&gt;8&lt;/sup&gt; PFU of vaccinia virus encoding the HA epitope. 3 wk later, splenocytes were harvested. Immunized mice are B10.D2 mice that express Influenza HA gene under the control of the insulin promoter.  CTLs were stimulated weekly with irradiated, peptide-loaded splenocytes.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HA 518-526</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IYSTVASSL</LinearSequence>
                                        <StartingPosition>533</StartingPosition>
                                        <EndingPosition>541</EndingPosition>
                                        <SourceMolecule>
                                            <IedbAccession>SRC133</IedbAccession>
                                        </SourceMolecule>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>CTL clones from Influenza infected B10.D2 (hetero and homozygotic) HA-transgenic mice have a lower relative affinity for peptide-MCH tetramers than in non-transgenic mice, since lower levels of binding are seen without a lower level of TCR expression. Clones from heterozygotic transgenic mice have a slightly higher level of TCR binding than those from homozygotic transgenic mice.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 6</LocationOfData>
                        <TCellId>21786</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000211</OrganismId>
                                <Age>&gt; 8 wk.</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1200 HA units</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>T cell</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>IYSTVASSL</LinearSequence>
                                            <StartingPosition>533</StartingPosition>
                                            <EndingPosition>541</EndingPosition>
                                            <SourceMolecule>
                                                <IedbAccession>SRC133</IedbAccession>
                                            </SourceMolecule>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>3 wks after infection, mice were boosted with 10&lt;sup&gt;8&lt;/sup&gt; PFU of vaccinia virus encoding the HA epitope. 3 wk later, splenocytes were harvested. Immunized mice are B10.D2 mice that express Influenza HA gene under the control of the insulin promoter.  CTLs were stimulated weekly with irradiated, peptide-loaded splenocytes.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellType>Fibroblast</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HA 518-526</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IYSTVASSL</LinearSequence>
                                        <StartingPosition>533</StartingPosition>
                                        <EndingPosition>541</EndingPosition>
                                        <SourceMolecule>
                                            <IedbAccession>SRC133</IedbAccession>
                                        </SourceMolecule>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>CTL clones from Influenza infected B10.D2 (hetero and homozygotic) HA-transgenic mice are able to produce IFN-g upon epitope stimulation, but the proportion is highly reduced in comparison to non-transgenic CTL clones, correlating with the limited lytic capacity of these cells, both at the polyclonal and monoclonal level.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>21782</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000051</OrganismId>
                                <Age>&gt; 8 wk.</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1200 HA units</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>T cell</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>IYSTVASSL</LinearSequence>
                                            <StartingPosition>533</StartingPosition>
                                            <EndingPosition>541</EndingPosition>
                                            <SourceMolecule>
                                                <IedbAccession>SRC133</IedbAccession>
                                            </SourceMolecule>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>3 wks after infection, mice were boosted with 10&lt;sup&gt;8&lt;/sup&gt; PFU of vaccinia virus encoding the HA epitope. 3 wk later, splenocytes were harvested.  CTLs were stimulated weekly with irradiated, peptide-loaded splenocytes.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>Fibroblast</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HA 518-526</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IYSTVASSL</LinearSequence>
                                        <StartingPosition>533</StartingPosition>
                                        <EndingPosition>541</EndingPosition>
                                        <SourceMolecule>
                                            <IedbAccession>SRC133</IedbAccession>
                                        </SourceMolecule>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Splenocytes from Influenza infected B10.D2 mice are able to effectively lyse peptide pulsed target cells, while lytic activity is highly reduced in congenic HA-transgenic mice splenocytes, showing that the CTL activity in the periphery is reduced in the transgenic mice. In adoptive transfer experiments, wild type CTLs have diabetogenic capacity, while the CTLs from transgenic mice do not. Similar results were obtained with CTL clones derived from lines that retained cytolytic activity over several restimulation passages. These differences are not due to Fas/FasL deficiency, diminished CD3-mediated signaling, or to a difference in the surface expression of TCR, CD8 or activation markers, nor to the enhanced expression of α/α TCRs. However, a differential peptide-MHC tetramer binding could be seen, indicating the relative affinity of the TCR is higher in wild type B10.D2 mice.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>21783</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000211</OrganismId>
                                <Age>&gt; 8 wk.</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1200 HA units</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>T cell</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>IYSTVASSL</LinearSequence>
                                            <StartingPosition>533</StartingPosition>
                                            <EndingPosition>541</EndingPosition>
                                            <SourceMolecule>
                                                <IedbAccession>SRC133</IedbAccession>
                                            </SourceMolecule>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>3 wks after infection, mice were boosted with 10&lt;sup&gt;8&lt;/sup&gt; PFU of vaccinia virus encoding the HA epitope. 3 wk later, splenocytes were harvested. Immunized mice are B10.D2 mice that express Influenza HA gene under the control of the insulin promoter.  CTLs were stimulated weekly with irradiated, peptide-loaded splenocytes.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>Fibroblast</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HA 518-526</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IYSTVASSL</LinearSequence>
                                        <StartingPosition>533</StartingPosition>
                                        <EndingPosition>541</EndingPosition>
                                        <SourceMolecule>
                                            <IedbAccession>SRC133</IedbAccession>
                                        </SourceMolecule>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Splenocytes from Influenza infected B10.D2 (hetero and homozygotic) HA-transgenic mice are able to lyse peptide pulsed target cells, but this activity is highly reduced in comparison to non-transgenic mice, showing the CTL activity in the periphery is reduced in the transgenic mice. In adoptive transfer experiments, wild type CTLs have diabetogenic capacity, while the CTLs from transgenic mice do not. Similar results were obtained with CTL clones derived from lines that retained cytolytic activity over several restimulation passages. These differences are not due to Fas/FasL deficiency, diminished CD3-mediated signaling, or to a difference in the surface expression of TCR, CD8 or activation markers, nor to the enhanced expression of α/α TCRs. However, a differential peptide-MHC tetramer binding could be seen, indicating the relative affinity of the TCR is higher in wild type B10.D2 mice.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

